View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 22, 2022

Acticor reports positive data from Phase Ib/IIa acute ischemic stroke trial

In the glenzocimab arm of the trial, the occurrence of deaths was 8% versus 19% in the placebo arm.

Acticor Biotech has reported positive data from its Phase Ib/IIa ACTIMIS clinical trial of glenzocimab analysed as an add-on treatment to standard of care for acute ischemic stroke (AIS) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Findings showed that the trial met the primary endpoint, establishing the favourable safety profile of glenzocimab. The company intends to validate the trial data in Phase III trials of glenzocimab.

The global, multicentre, randomised, double-blind, placebo-controlled trial analysed the tolerability and efficacy of glenzocimab. 

As per the European Medicines Agency (EMA) advice, the Phase Ib portion of the trial had dose escalation and parallel cohorts to analyse either 125, 250, 500, 1000mg doses of glenzocimab or placebo.

The subsequent phase IIa segment analysed 1000mg of the treatment compared to placebo as an add-on to the standard of care. 

The trial was conducted in six countries in Europe enrolling 166 subjects.

Tolerability, including the incidence of intracerebral haemorrhage (ICH) and mortality was the primary endpoint of the trial.

This endpoint was attained in all trial subjects with the occurrence of symptomatic ICH reduced in glenzocimab treated subjects versus placebo plus standard of care.

In the glenzocimab arm, a 1% symptomatic ICH incidence was reported as against 8% in the placebo arm. 

Similarly, imaging showed that asymptomatic ICH incidence was reported in 31% of subjects in the glenzocimab arm versus 48% treated with placebo.

Furthermore, in the entire study population, there was a lower incidence of deaths among patients receiving the therapy versus placebo.

In the glenzocimab arm, the occurrence of deaths was 8% versus 19% in the placebo arm.

The latest data showed that glenzocimab possesses favourable tolerability profile when given along with reperfusion therapies in the acute phase, including thrombolysis irrespective of thrombectomy status.

According to a survival assessment in the Phase IIa study, glenzocimab offered a nearly threefold decline in the number of deaths as well as its later occurrence.

A humanised monoclonal antibody (mAb) fragment, glenzocimab acts on platelet glycoprotein VI (GPVI). It hinders platelet from attaching to the thrombus without impacting physiological haemostasis, to aid in preventing the risk of bleeding, especially in the brain.

Acticor Biotech chief medical officer and general manager Dr Yannick Plétan said: “Across the entire treated population, a reduction in the number of intracerebral haemorrhages was seen with glenzocimab and in Phase IIa fewer patients experienced severe disability or death (mRS scores of 4, 5 or 6). 

“The study has therefore confirmed the clinical benefit of inhibiting GPVI, and these findings tally with recently published laboratory data on the expression of platelet GPVI in patients in the acute phase of stroke.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena